Predictive Biosciences was a stimulation and exciting place to work. I was given much freedom and responsibility during my tenure there and we achieved much success with the commercialization and adoption of our molecular diagnostics tests for bladder cancer.
This start up had certain vulnerabilities, as every start up has. With a recent Medicare decision that was adverse, the VC board decided to close up shop instead of working through the issues. This was disappointing to the employees, obviously, but also to the urology community which no longer has access to the diagnostic tests.